We bring precision, speed, and flexibility to contamination testing, redefining quality assurance in manufacturing.
HelioWave enables quick and accurate detection of contamination, reducing testing time by up to 75% and allowing manufacturers to respond swiftly to ensure product safety.
With real-time data and continuous monitoring capabilities, HelioWave ensures automated compliance with USP <71> standards, helping manufacturers maintain stringent safety and quality benchmarks.
HelioWave offers versatile testing options, including off-site, on-site at-line, and real-time monitoring, so clients can adapt testing to their unique workflows and enhance efficiency.
HelioWave lowers testing costs by streamlining quality control processes, reducing manual interventions, and providing rapid results, ultimately minimizing production downtime and waste.
We’re partnering with industry leaders to improve testing solutions and elevate biopharma safety and quality.
We're in three top incubators, gaining vital resources and mentorship to accelerate growth.
We've secured over $2.5M in funding from DARPA, NIH, USDA SBIR grants, and the BARDA BlueKnight program.
Fueling Success with Cutting-Edge Technology.
Empowering Safety Through Innovation.
Safe, Precise, and Innovative Testing Solutions.
HelioWave provides cutting-edge solutions across various industries, ensuring optimal performance, safety, and efficiency. Whether it’s pharmaceutical workflows, food safety technologies, or everyday product logistics, our innovations reliably deliver contamination-free results, helping clients meet the highest standards and maintain consumer trust.
We understand that quality testing systems must align closely with specific workflows, and their efficiency can be heavily influenced by operational settings. That’s why we are committed to supporting each application on a case-by-case basis. HelioWave offers customizable platforms and flexible detection modalities tailored to meet the unique needs of diverse biomanufacturing processes.
We are a proud spin-out from Texas A&M University, founded by a research team with deep expertise in microfluidic technologies. Collectively, our team has been awarded over $100 million in research funding and is dedicated to innovating impactful diagnostic platforms for biomedical applications.
HelioWave has received competitive SBIR awards from DARPA, NIH, and USDA to support the advancement and commercialization of its technologies. In addition, the company is backed by Capital Factory and the HHS/BARDA Blue Knight accelerator program, which provide strategic support for business development and growth.
We collaborate with pharmaceutical companies, biomanufacturing facilities, and government agencies to enhance the safety and quality of drugs and food products.
Yes! We are actively seeking industry partners to validate and co-develop our system for specific production workflows. If you're interested in collaboration, we’d love to hear from you—please contact us to explore partnership opportunities.